Immune Pharmaceuticals Announces Publication of New Data on Eotaxin-1 in IBD; Patient Enrollment in Phase II UC Trial Continues

NEW YORK, Feb. 24, 2016 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP), “Immune”, a clinical-stage biopharmaceutical company, announces publication of new data on the role of eotaxin-1 in Ulcerative Colitis (UC) and Crohn’s Disease (CD). The article, published in Digestive Disease Science 1, presents results of an observational clinical study intended to characterize serum and intestinal…